4.54
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SLDB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$4.25
Offen:
$4.31
24-Stunden-Volumen:
1.61M
Relative Volume:
1.07
Marktkapitalisierung:
$248.82M
Einnahmen:
$14.79M
Nettoeinkommen (Verlust:
$-102.44M
KGV:
-1.4934
EPS:
-3.04
Netto-Cashflow:
$-91.73M
1W Leistung:
+41.43%
1M Leistung:
+34.72%
6M Leistung:
-10.10%
1J Leistung:
-41.19%
Solid Biosciences Inc Stock (SLDB) Company Profile
Firmenname
Solid Biosciences Inc
Sektor
Branche
Telefon
617-337-4680
Adresse
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Vergleichen Sie SLDB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SLDB
Solid Biosciences Inc
|
4.54 | 248.82M | 14.79M | -102.44M | -91.73M | -3.04 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-01-08 | Eingeleitet | Truist | Buy |
2024-12-13 | Eingeleitet | Wedbush | Outperform |
2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
2024-07-15 | Hochstufung | JP Morgan | Neutral → Overweight |
2024-06-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
2024-03-28 | Eingeleitet | William Blair | Outperform |
2024-03-15 | Eingeleitet | Citigroup | Buy |
2024-03-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
2021-07-12 | Eingeleitet | Piper Sandler | Neutral |
2021-05-27 | Eingeleitet | Jefferies | Buy |
2021-03-16 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2021-03-09 | Eingeleitet | Barclays | Overweight |
2021-01-08 | Hochstufung | Credit Suisse | Underperform → Neutral |
2020-07-28 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-05-07 | Herabstufung | Evercore ISI | Outperform → In-line |
2019-10-11 | Eingeleitet | Evercore ISI | Outperform |
2019-08-29 | Herabstufung | Citigroup | Neutral → Sell |
2019-08-19 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2019-08-16 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2019-05-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
2019-05-14 | Herabstufung | Goldman | Neutral → Sell |
2019-02-08 | Hochstufung | Citigroup | Sell → Neutral |
2019-02-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2018-11-06 | Eingeleitet | Citigroup | Sell |
2018-09-06 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten
Solid Biosciences (SLDB) Maintains Market Outperform Rating | SLDB Stock News - GuruFocus
Transcript : Solid Biosciences Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Solid Biosciences (SLDB) Announces Stock Grants Under Inducement Plan | SLDB Stock News - GuruFocus
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences Awards Strategic RSU Grants: New Hires Receive 34,550 Shares Under Nasdaq Compensation Rule - Stock Titan
Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Northern Trust Corp Has $676,000 Stake in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Reports Increased Loss Amid R&D Expansion - TipRanks
BNP Paribas Financial Markets Acquires New Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
D. E. Shaw & Co. Inc. Buys Shares of 51,972 Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences to Participate at the Jefferies Global Healthcare Conference - GlobeNewswire
Solid Biosciences Leadership Team to Reveal Latest Genetic Medicine Strategy at Major Healthcare Conference - Stock Titan
Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough - Investing.com Nigeria
Research Analysts Set Expectations for SLDB FY2025 Earnings - Defense World
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fi - GuruFocus
Solid Biosciences (SLDB) Receives Overweight Rating by Cantor Fitzgerald | SLDB Stock News - GuruFocus
Solid Biosciences (NASDAQ:SLDB) Given New $15.00 Price Target at Chardan Capital - Defense World
Solid Biosciences (SLDB) Maintains Buy Rating Amid Revised Price Target | SLDB Stock News - GuruFocus
Chardan Adjusts Price Target on Solid Biosciences to $15 From $16, Maintains Buy Rating - marketscreener.com
Q1 Earnings Forecast for SLDB Issued By William Blair - Defense World
Wedbush Issues Pessimistic Forecast for Solid Biosciences (NASDAQ:SLDB) Stock Price - Defense World
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance
Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus
SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus
Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com
Solid Biosciences (SLDB) Target Price Updated by Wedbush Analyst - GuruFocus
Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus
Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com
Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks
Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus
Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com
Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks
SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus
Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com
Form 424B5 Solid Biosciences Inc. - StreetInsider
Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates | SLDB Stock News - GuruFocus
Solid Biosciences Provides Business Update and Financial Results for Q1 2025, Advances Gene Therapy Programs for Duchenne Muscular Dystrophy, Friedreich's Ataxia, and CPVT - Nasdaq
Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Solid Biosciences Reports Breakthrough in Duchenne Treatment: Q1 Results Reveal Strong Pipeline Progress - Stock Titan
Solid Biosciences (SLDB) Expected to Announce Earnings on Wednesday - Defense World
Partner With Us - Solid Biosciences
Solid Biosciences Reports Quarterly Loss Per Share Of $0.54 - Reuters
Analysts Have Conflicting Sentiments on These Healthcare Companies: Axsome Therapeutics (AXSM), Premier (PINC) and Solid Biosciences (SLDB) - The Globe and Mail
Solve FSHD supports Armatus Bio drug for facioscapulohumeral muscular dystrophy - BioWorld MedTech
Invesco Ltd. Invests $49,000 in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Finanzdaten der Solid Biosciences Inc-Aktie (SLDB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):